DVYSR — Devyser Diagnostics AB Share News
0.000.00%
Last trade - 00:00- SEK1.42bn
- SEK1.39bn
- SEK250.50m
Brief: Devyser Diagnostics Is Not Proposing Dividend For 2023
Brief: Devyser Q4 Sales SEK 45.4 Million
Brief: Devyser Genomic Laboratories Signs First Commercial Agreement
Brief: Devyser Diagnostics Wins Tender In Italy
Brief: Devyser Signs In Vitro Diagnostic Agreement With Illumina
Brief: Devyser Wins Tender For Cystic Fibrosis
Brief: Devyser Wins Tender For Non-Invasive Fetal RHD Testing In Wales
Brief: Devyser Q3 Sales SEK 46.7 Million
Brief: Devyser, Thermo Fisher Scientific Collaborate To Promote Laboratory Services To Advance Pharmaceutical Research
Brief: Devyser, Thermo Fisher Scientific Collaborate
Brief: Devyser And Thermo Fisher Scientific Expand Collaboration
Brief: Devyser Q2 Sales at SEK 37.7 Million
Brief: Devyser's NGS Products For Monitoring Of Kidney And Stem Cell Transplanted Patients Receive IVDR Approvals
Brief: Approval Of Devyser's RHD Product In Canada
Brief: Devyser Diagnostics Q1 Operating Loss Widens To SEK 19.1 Mln
Brief: Devyser Q1 Adj. EPS at SEK -1.24
Brief: Thermo Fisher Scientific To Commercialize Devyser's Post-Transplant NGS Products
Brief: Devyser Diagnostics Launches First IVDR-Certified Product
Brief: Devyser Q4 Sales SEK 34.2 Million